PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33020270-5	2020	Importantly, combining olaparib with NU7441, a DNA-PKcs inhibitor that blocks NHEJ in HCC, synergistically suppressed HCC growth in both mice and HCC patient-derived-xenograft models.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	37-43	protein kinase, DNA activated, catalytic polypeptide	Mus musculus	47-55
33389482-8	2021	SCR7 blocks Ligase IV-mediated joining by interfering with its DNA binding, whereas NU7441 is a highly potent and selective DNA-PK inhibitor.II.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	84-90	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	124-130
33074046-12	2020	Conclusions: DNA-PK inhibitor NU7441 radiosensitized 2D cultured NT2.5 monolayer cells but not cells obtained from 3D cultured spheroids.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	30-36	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	13-19
33571522-7	2021	Pretreatment of parotid cells with the DNA-PK inhibitor NU7441 reversed the increase in DNA repair induced by TKIs.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	56-62	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	39-45
33133138-4	2020	Here, we show that the combination of the DNA-PK inhibitor NU7441 and the PARP inhibitor olaparib significantly decrease proliferation (61-78%) compared to no reduction with either agent alone (p < 0.001) in both SCC1 and SCC6 cell lines.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	59-65	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	42-48
32213959-8	2020	Pretreatment of NU7441, a small molecule inhibitor of DNA-activated protein kinase (DNA-PK) suppressed PGA2-induced phosphorylation of p53 and apoptosis as well.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	16-22	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	54-82
32213959-8	2020	Pretreatment of NU7441, a small molecule inhibitor of DNA-activated protein kinase (DNA-PK) suppressed PGA2-induced phosphorylation of p53 and apoptosis as well.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	16-22	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	84-90
32213959-8	2020	Pretreatment of NU7441, a small molecule inhibitor of DNA-activated protein kinase (DNA-PK) suppressed PGA2-induced phosphorylation of p53 and apoptosis as well.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	16-22	tumor protein p53	Homo sapiens	135-138
31583565-14	2020	Our findings suggest that NK314 could overcome resistance of MO59 cells to VP-16 and NU7441 could serve as sensitizer to VP-16/NK314 combined treatment.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	85-91	host cell factor C1	Homo sapiens	121-126
31785810-6	2020	Inhibition of DNA-PKcs by NU7441 significantly impaired DNA repair and re-sensitized resistant UM cells to radiation and Selumetinib both in vitro and in vivo.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	26-32	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	14-22
31583565-7	2020	In this work we investigated the effect of two Top2 inhibitors NK314 and VP-16 in glioma cell lines (MO59 K and MO59 J) sensitized by DNA-PK inhibitor, NU7441.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	152-158	host cell factor C1	Homo sapiens	73-78
28580318-7	2017	On the other hand, inhibition of the other route involved in DSB repair, non-homologous end joining (NHEJ), using the DNA-PK inhibitor NU7441, did not affect MM cell viability.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	135-141	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	118-124
31672611-11	2020	The DNA-PK inhibitor, NU7441, could significantly inhibit DNA-PK and Ku70 expression, simultaneously further aggravating BP-induced apoptosis and DNA damage under high-glucose conditions.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	22-28	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	4-10
31672611-11	2020	The DNA-PK inhibitor, NU7441, could significantly inhibit DNA-PK and Ku70 expression, simultaneously further aggravating BP-induced apoptosis and DNA damage under high-glucose conditions.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	22-28	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	58-64
31672611-11	2020	The DNA-PK inhibitor, NU7441, could significantly inhibit DNA-PK and Ku70 expression, simultaneously further aggravating BP-induced apoptosis and DNA damage under high-glucose conditions.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	22-28	X-ray repair cross complementing 6	Homo sapiens	69-73
31490091-8	2019	Radiosensitization by IC87361 and olaparib was significantly enhanced under acute anoxia and chronic hypoxia.Conclusions: The DNA-PK inhibitors KU57788 and IC87361 are more effective radiosensitizers than the PARP-1 inhibitors olaparib and veliparib at non-cytotoxic concentrations in HNSCC cell cultures and their activity is enhanced by SLFN11 and hypoxia.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	144-151	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	126-132
31490091-8	2019	Radiosensitization by IC87361 and olaparib was significantly enhanced under acute anoxia and chronic hypoxia.Conclusions: The DNA-PK inhibitors KU57788 and IC87361 are more effective radiosensitizers than the PARP-1 inhibitors olaparib and veliparib at non-cytotoxic concentrations in HNSCC cell cultures and their activity is enhanced by SLFN11 and hypoxia.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	144-151	poly(ADP-ribose) polymerase 1	Homo sapiens	209-215
31490091-8	2019	Radiosensitization by IC87361 and olaparib was significantly enhanced under acute anoxia and chronic hypoxia.Conclusions: The DNA-PK inhibitors KU57788 and IC87361 are more effective radiosensitizers than the PARP-1 inhibitors olaparib and veliparib at non-cytotoxic concentrations in HNSCC cell cultures and their activity is enhanced by SLFN11 and hypoxia.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	144-151	schlafen family member 11	Homo sapiens	339-345
31362335-7	2019	Similarly, co-treatment with PF-477736 and NU7441, a pharmacological inhibitor of DNA-PK, which is also essential for the DDR pathway, rendered the cells sensitive to CHK1 inhibition.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	43-49	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	82-88
31362335-7	2019	Similarly, co-treatment with PF-477736 and NU7441, a pharmacological inhibitor of DNA-PK, which is also essential for the DDR pathway, rendered the cells sensitive to CHK1 inhibition.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	43-49	checkpoint kinase 1	Homo sapiens	167-171
30476230-9	2019	This correlation was not observed after treatment with NU7441, a DNA-PK-specific inhibitor.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	55-61	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	65-71
28821159-5	2017	Here, we show that the DNA-PK inhibitor NU7441 increased doxorubicin-induced apoptosis in BCP-ALL cell lines (NALM-6, SUP-B15), correlating with a reduction in DSB repair measured by gamma-H2AX foci.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	40-46	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	23-29
28821159-7	2017	Doxorubicin-induced DNA-PK phosphorylation was decreased in the presence of NU7441.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	76-82	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	20-26
31464599-5	2019	Chronic inhibition of DNA-PKcs kinase activity was mimicked using a highly specific small molecule inhibitor, Nu7441.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	110-116	dna-pkcs	None	22-30
30964658-9	2019	HN2-induced cell cycle arrest was suppressed by the ATM and DNA-PK inhibitors, KU55933 and NU7441, respectively, and to a lesser extent by VE821, an ATR inhibitor.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	91-97	MT-RNR2 like 2 (pseudogene)	Homo sapiens	0-3
30964658-9	2019	HN2-induced cell cycle arrest was suppressed by the ATM and DNA-PK inhibitors, KU55933 and NU7441, respectively, and to a lesser extent by VE821, an ATR inhibitor.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	91-97	ATM serine/threonine kinase	Homo sapiens	52-55
30964658-9	2019	HN2-induced cell cycle arrest was suppressed by the ATM and DNA-PK inhibitors, KU55933 and NU7441, respectively, and to a lesser extent by VE821, an ATR inhibitor.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	91-97	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	60-66
28780388-10	2018	p-AKT and p-S6 activation by Mn is almost completely blocked upon addition of NU7441(5muM) or LY294002(7muM), supporting PI3K"s upstream role in the AKT/mTOR pathway.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	78-84	thymoma viral proto-oncogene 1	Mus musculus	2-5
28780388-10	2018	p-AKT and p-S6 activation by Mn is almost completely blocked upon addition of NU7441(5muM) or LY294002(7muM), supporting PI3K"s upstream role in the AKT/mTOR pathway.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	78-84	thymoma viral proto-oncogene 1	Mus musculus	149-152
28780388-10	2018	p-AKT and p-S6 activation by Mn is almost completely blocked upon addition of NU7441(5muM) or LY294002(7muM), supporting PI3K"s upstream role in the AKT/mTOR pathway.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	78-84	mechanistic target of rapamycin kinase	Mus musculus	153-157
27702817-10	2017	The DNA-PK inhibitor, NU7441, induced resistance to rucaparib (P = 0.014) and HR function recovery in a BRCA1-defective cell line.Conclusions: This study has shown that NHEJ is defective in 40% of ovarian cancers, which is independent of HR function and associated with resistance to PARP inhibitors in ex vivo primary cultures.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	22-28	BRCA1 DNA repair associated	Homo sapiens	104-109
27702817-10	2017	The DNA-PK inhibitor, NU7441, induced resistance to rucaparib (P = 0.014) and HR function recovery in a BRCA1-defective cell line.Conclusions: This study has shown that NHEJ is defective in 40% of ovarian cancers, which is independent of HR function and associated with resistance to PARP inhibitors in ex vivo primary cultures.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	22-28	collagen type XI alpha 2 chain	Homo sapiens	284-288
27602767-3	2016	By suppressing DNA-DSB repair with hyperthermia (HT) and DNA-PKcs inhibitor NU7441 (DNA-PKcsi), we aim to enhance the effect of radiation.The sensitizing effect of HT for 1 hour at 42 C and DNA-PKcsi [1 muM] to radiation treatment was investigated in cervical and breast cancer cells, primary breast cancer sphere cells (BCSCs) enriched for cancer stem cells, and in an in vivo human tumor model.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	76-82	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	57-65
28331416-0	2017	DNA-PK Inhibition by NU7441 Enhances Chemosensitivity to Topoisomerase Inhibitor in Non-Small Cell Lung Carcinoma Cells by Blocking DNA Damage Repair.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	21-27	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	0-6
28331416-4	2017	In this study, we investigated the effect of NU7441, a synthetic small-molecule compound, as a specific inhibitor of DNA-PK on the chemosensitization of non-small cell lung carcinoma (NSCLC) A549 cells.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	45-51	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	117-123
27935869-7	2017	Results from this study showed that the combination of cisplatin, DNA-PK inhibitor NU7441, and AKT inhibitor TCN can overcome drug resistance, increase apoptosis, and re-sensitize PEO4 cells to cisplatin treatment.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	83-89	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	66-72
26381179-5	2015	DNA-PKcs inhibitors, including NU7026 and NU7441, dramatically enhanced WAY-600-induced cytotoxic and pro-apoptotic effect against the CRC cells.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	42-48	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	0-8
27341700-10	2016	In summary, NSCLC cells irradiated with carbon ions were radio-sensitized by a low concentration of DNA-PK inhibitor NU7441 through a strong G2/M cell cycle arrest.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	117-123	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	100-106
27412013-5	2016	In vivo, DNA-PKcs knockdown or oral administration of the DNA-PKcs inhibitor NU-7441 inhibited AKT Ser-473 phosphorylation, HIF-2alpha expression and 786-0 RCC xenograft growth in nude mice.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	77-84	protein kinase, DNA activated, catalytic polypeptide	Mus musculus	58-66
27412013-5	2016	In vivo, DNA-PKcs knockdown or oral administration of the DNA-PKcs inhibitor NU-7441 inhibited AKT Ser-473 phosphorylation, HIF-2alpha expression and 786-0 RCC xenograft growth in nude mice.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	77-84	thymoma viral proto-oncogene 1	Mus musculus	95-98
27412013-5	2016	In vivo, DNA-PKcs knockdown or oral administration of the DNA-PKcs inhibitor NU-7441 inhibited AKT Ser-473 phosphorylation, HIF-2alpha expression and 786-0 RCC xenograft growth in nude mice.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	77-84	endothelial PAS domain protein 1	Mus musculus	124-134
27160694-3	2016	In this study, we investigated the effect of NU7441, a synthetic small-molecule compound, as a specific inhibitor of DNA-dependent protein kinase (DNA-PK) in radiosensitization of hepatocellular carcinoma HepG2 cells.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	45-51	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	117-145
27160694-3	2016	In this study, we investigated the effect of NU7441, a synthetic small-molecule compound, as a specific inhibitor of DNA-dependent protein kinase (DNA-PK) in radiosensitization of hepatocellular carcinoma HepG2 cells.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	45-51	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	147-153
27643582-2	2016	We demonstrated that DNA-PK inhibitor NU7441 enhanced phosphorylation of Chk1 and Chk2 kinases 2 h after irradiation of HeLa cells at a dose of 8 Gy in contrast to ATM kinase inhibitor KU55933, which completely blocked the Chk2 kinase phosphorylation on threonine 68, and ATR kinase inhibitor VE-821, which blocked the Chk1 kinase phosphorylation on serine 345.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	38-44	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	21-27
27643582-2	2016	We demonstrated that DNA-PK inhibitor NU7441 enhanced phosphorylation of Chk1 and Chk2 kinases 2 h after irradiation of HeLa cells at a dose of 8 Gy in contrast to ATM kinase inhibitor KU55933, which completely blocked the Chk2 kinase phosphorylation on threonine 68, and ATR kinase inhibitor VE-821, which blocked the Chk1 kinase phosphorylation on serine 345.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	38-44	checkpoint kinase 1	Homo sapiens	73-77
27643582-2	2016	We demonstrated that DNA-PK inhibitor NU7441 enhanced phosphorylation of Chk1 and Chk2 kinases 2 h after irradiation of HeLa cells at a dose of 8 Gy in contrast to ATM kinase inhibitor KU55933, which completely blocked the Chk2 kinase phosphorylation on threonine 68, and ATR kinase inhibitor VE-821, which blocked the Chk1 kinase phosphorylation on serine 345.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	38-44	checkpoint kinase 2	Homo sapiens	82-86
27643582-2	2016	We demonstrated that DNA-PK inhibitor NU7441 enhanced phosphorylation of Chk1 and Chk2 kinases 2 h after irradiation of HeLa cells at a dose of 8 Gy in contrast to ATM kinase inhibitor KU55933, which completely blocked the Chk2 kinase phosphorylation on threonine 68, and ATR kinase inhibitor VE-821, which blocked the Chk1 kinase phosphorylation on serine 345.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	38-44	checkpoint kinase 2	Homo sapiens	223-227
27643582-2	2016	We demonstrated that DNA-PK inhibitor NU7441 enhanced phosphorylation of Chk1 and Chk2 kinases 2 h after irradiation of HeLa cells at a dose of 8 Gy in contrast to ATM kinase inhibitor KU55933, which completely blocked the Chk2 kinase phosphorylation on threonine 68, and ATR kinase inhibitor VE-821, which blocked the Chk1 kinase phosphorylation on serine 345.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	38-44	ATR serine/threonine kinase	Homo sapiens	272-275
27643582-2	2016	We demonstrated that DNA-PK inhibitor NU7441 enhanced phosphorylation of Chk1 and Chk2 kinases 2 h after irradiation of HeLa cells at a dose of 8 Gy in contrast to ATM kinase inhibitor KU55933, which completely blocked the Chk2 kinase phosphorylation on threonine 68, and ATR kinase inhibitor VE-821, which blocked the Chk1 kinase phosphorylation on serine 345.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	38-44	checkpoint kinase 1	Homo sapiens	319-323
25771720-7	2014	This was in strong contrast to cells completely lacking DNA-PKcs and cells treated with the DNA-PKcs inhibitor NU7441, in which DSB repair were severely compromised.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	111-117	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	92-100
25441643-5	2015	Administration of the DNA-PK inhibitor NU7441 reduced airway eosinophilia, mucus hypersecretion, airway hyperresponsiveness, and OVA-specific IgE production in mice prechallenged with OVA.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	39-45	protein kinase, DNA activated, catalytic polypeptide	Mus musculus	22-28
25714019-2	2015	Several studies have shown that the DNA-PKcs inhibitor NU7441 is a highly potent radiosensitizer, however, the mechanism of NU7441"s anti-proliferation effect has not been fully elucidated.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	55-61	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	36-44
24418411-9	2014	This paper demonstrates that NU7441 is a dual DNA-PK and MDR1 inhibitor, and this extends the therapeutic potential of the compound when used in combination with MDR substrates.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	29-35	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	46-52
25152407-4	2014	We found that NU-7026 and NU-7441, two DNA-PKcs inhibitors, enhanced gemcitabine-induced cytotoxicity and apoptosis in PANC-1 pancreatic cancer cells.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	26-33	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	39-47
24418411-4	2014	NU7441 is a potent DNA-PK inhibitor (IC50=14nM) that is used widely to study the effects of DNA-PK inhibition in vitro.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	0-6	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	19-25
24418411-4	2014	NU7441 is a potent DNA-PK inhibitor (IC50=14nM) that is used widely to study the effects of DNA-PK inhibition in vitro.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	0-6	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	92-98
25264192-7	2014	Co-immunoprecipitation (Co-IP) assay results demonstrated that LDI-induced DNA-PKcs-SIN1 complexation, which was inhibited by NU-7441 or SIN1 siRNA-knockdown in mouse osteoblasts.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	126-133	protein kinase, DNA activated, catalytic polypeptide	Mus musculus	75-83
25264192-7	2014	Co-immunoprecipitation (Co-IP) assay results demonstrated that LDI-induced DNA-PKcs-SIN1 complexation, which was inhibited by NU-7441 or SIN1 siRNA-knockdown in mouse osteoblasts.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	126-133	mitogen-activated protein kinase associated protein 1	Mus musculus	84-88
24418411-9	2014	This paper demonstrates that NU7441 is a dual DNA-PK and MDR1 inhibitor, and this extends the therapeutic potential of the compound when used in combination with MDR substrates.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	29-35	ATP binding cassette subfamily B member 1	Homo sapiens	57-61
23308052-5	2012	A novel DNA-PKcs inhibitor NU7441 can significantly enhance the effect of radiation in DAB2IP-deficient PCa cells.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	27-33	DAB2 interacting protein	Homo sapiens	87-93
24100951-0	2014	Radio-sensitization of human leukaemic MOLT-4 cells by DNA-dependent protein kinase inhibitor, NU7441.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	95-101	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	55-83
24100951-1	2014	We studied the effect of pre-incubation with NU7441, a specific inhibitor of DNA-dependent protein kinase (DNA-PK), on molecular mechanisms triggered by ionizing radiation (IR).	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	45-51	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	77-105
24100951-1	2014	We studied the effect of pre-incubation with NU7441, a specific inhibitor of DNA-dependent protein kinase (DNA-PK), on molecular mechanisms triggered by ionizing radiation (IR).	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	45-51	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	107-113
16707462-0	2006	Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	80-86	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	41-69
22814419-1	2012	Substitution at the 7-position of the chromen-4-one pharmacophore of 8-(dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-one NU7441, a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor, with allyl, n-propyl or methyl enabled the resolution by chiral HPLC of atropisomers.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	69-128	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	160-188
22814419-1	2012	Substitution at the 7-position of the chromen-4-one pharmacophore of 8-(dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-one NU7441, a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor, with allyl, n-propyl or methyl enabled the resolution by chiral HPLC of atropisomers.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	69-128	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	190-196
21630086-0	2012	Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	75-81	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	57-63
21630086-3	2012	The purpose of this study was to further characterise the activity of the DNA-PK inhibitor NU7441, giving some new insights into the biology of DNA-PK.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	91-97	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	74-80
21630086-3	2012	The purpose of this study was to further characterise the activity of the DNA-PK inhibitor NU7441, giving some new insights into the biology of DNA-PK.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	91-97	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	144-150
21083655-6	2011	NU7441 prevented mitoxantrone-induced autophosphorylation of the DNA-PK catalytic subunit (DNA-PKcs) at Ser 2056, confirming that DNA-PK participates in repair of mitoxantrone-induced DNA damage.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	0-6	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	65-89
21083655-6	2011	NU7441 prevented mitoxantrone-induced autophosphorylation of the DNA-PK catalytic subunit (DNA-PKcs) at Ser 2056, confirming that DNA-PK participates in repair of mitoxantrone-induced DNA damage.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	0-6	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	91-99
21083655-6	2011	NU7441 prevented mitoxantrone-induced autophosphorylation of the DNA-PK catalytic subunit (DNA-PKcs) at Ser 2056, confirming that DNA-PK participates in repair of mitoxantrone-induced DNA damage.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	0-6	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	65-71
17526517-6	2007	A specific inhibitor of the kinase activity of DNA-PK, KU57788, completely blocked end joining promoted by wild type as well as both mutant forms of DNA-PK, while inhibition of ATM kinase did not.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	55-62	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	47-53
17526517-6	2007	A specific inhibitor of the kinase activity of DNA-PK, KU57788, completely blocked end joining promoted by wild type as well as both mutant forms of DNA-PK, while inhibition of ATM kinase did not.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	55-62	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	149-155
21546556-6	2011	Furthermore, both the DNA-PK inhibitor 8-(4-dibenzothienyl)-2-(4-morpholinyl)-4H-1-benzopyran-4-one (NU7441) and the ATM inhibitor 2-(4-morpholinyl)-6-(1-thianthrenyl)-4H-pyran-4-one (KU55933) significantly sensitized cells to NK314.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	39-99	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	22-28
17165896-1	2006	[Structure: see text] 2-morpholin-4-yl-4-oxo-4H-chromen-8-yl 2,2,2-trifluoromethanesulfonate is a key intermediate for the synthesis of the DNA-dependent protein kinase (DNA-PK) inhibitor 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one (NU7441).	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	188-241	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	140-168
17165896-1	2006	[Structure: see text] 2-morpholin-4-yl-4-oxo-4H-chromen-8-yl 2,2,2-trifluoromethanesulfonate is a key intermediate for the synthesis of the DNA-dependent protein kinase (DNA-PK) inhibitor 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one (NU7441).	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	188-241	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	170-176
17165896-1	2006	[Structure: see text] 2-morpholin-4-yl-4-oxo-4H-chromen-8-yl 2,2,2-trifluoromethanesulfonate is a key intermediate for the synthesis of the DNA-dependent protein kinase (DNA-PK) inhibitor 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one (NU7441).	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	243-249	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	140-168
17165896-1	2006	[Structure: see text] 2-morpholin-4-yl-4-oxo-4H-chromen-8-yl 2,2,2-trifluoromethanesulfonate is a key intermediate for the synthesis of the DNA-dependent protein kinase (DNA-PK) inhibitor 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one (NU7441).	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	243-249	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	170-176
15546735-2	2004	These studies resulted in the identification of 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one (NU7441) as a highly potent and selective DNA-PK inhibitor (IC50=14 nM), exhibiting ATP-competitive inhibition kinetics.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	48-101	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	144-150
15546735-0	2004	Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	97-103	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	48-76
15546735-0	2004	Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	97-103	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	78-84
15546735-2	2004	These studies resulted in the identification of 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one (NU7441) as a highly potent and selective DNA-PK inhibitor (IC50=14 nM), exhibiting ATP-competitive inhibition kinetics.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	103-109	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	144-150
35097256-7	2022	Moreover, a combination treatment with olaparib (a PARP1 inhibitor) and NU7441 (a DNA-PKcs inhibitor) sensitized NPC cells to VP-16 in vitro and in vivo, suggesting that the combined treatment of olaparib, NU7441, and a DNA-damaging agent may be a successful treatment regimen in patients with NPC.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	72-78	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	82-90
32890138-4	2021	METHODS: Fully MHC mismatched murine allogeneic skin graft studies were performed by transplanting skin from BalbC mice to C57bl6 mice and treating with either vehicle or the DNA-PKcs inhibitor NU7441.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	194-200	protein kinase, DNA activated, catalytic polypeptide	Mus musculus	175-183
34193614-9	2021	Pharmacological inhibition of DNA-PKcs with the DNA-PKcs inhibitor NU7441 reduced GSC tumorsphere formation in vitro and impaired growth of intracranial human GBM xenografts in mice as well as sensitized the GBM xenografts to radiotherapy.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	67-73	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	30-38
34193614-9	2021	Pharmacological inhibition of DNA-PKcs with the DNA-PKcs inhibitor NU7441 reduced GSC tumorsphere formation in vitro and impaired growth of intracranial human GBM xenografts in mice as well as sensitized the GBM xenografts to radiotherapy.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	67-73	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	48-56
34627777-7	2021	Likewise, erlotinib, an EGFR inhibitor, and NU7441, a DNA-PK inhibitor increased the expression of E-cadherin and decreased the level of vimentin.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	44-50	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	54-60
34627777-7	2021	Likewise, erlotinib, an EGFR inhibitor, and NU7441, a DNA-PK inhibitor increased the expression of E-cadherin and decreased the level of vimentin.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	44-50	cadherin 1	Homo sapiens	99-109
34627777-7	2021	Likewise, erlotinib, an EGFR inhibitor, and NU7441, a DNA-PK inhibitor increased the expression of E-cadherin and decreased the level of vimentin.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	44-50	vimentin	Homo sapiens	137-145
34337875-8	2021	The level of AURKA was significantly associated with the resistance to SB 505124, NU-7441, and irinotecan drugs (p < 0.01).	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	82-89	aurora kinase A	Homo sapiens	13-18
35457081-8	2022	Some of DNA-PK inhibitors, e.g., NU7026 and NU7441, have been used extensively in the studies for cellular function of DNA-PK.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	44-50	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	8-14
35457081-8	2022	Some of DNA-PK inhibitors, e.g., NU7026 and NU7441, have been used extensively in the studies for cellular function of DNA-PK.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	44-50	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	119-125
35085879-8	2022	NHEJ DRC measurements in cryopreserved PBMCs are quantifiable with low interindividual and inter-assay variability, and a titratable decrease in NHEJ activity was observed in PBMCs treated with the DNA-PK inhibitor NU7441.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	215-221	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	198-204
35097256-7	2022	Moreover, a combination treatment with olaparib (a PARP1 inhibitor) and NU7441 (a DNA-PKcs inhibitor) sensitized NPC cells to VP-16 in vitro and in vivo, suggesting that the combined treatment of olaparib, NU7441, and a DNA-damaging agent may be a successful treatment regimen in patients with NPC.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	72-78	host cell factor C1	Homo sapiens	126-131
34987222-4	2022	Here we report cryo-electron microscopy (cryo-EM) structures of human DNA-PKcs natively purified from HeLa cell nuclear extracts, in complex with adenosine-5"-(gamma-thio)-triphosphate (ATPgammaS) and four inhibitors (wortmannin, NU7441, AZD7648 and M3814), including drug candidates undergoing clinical trials.	8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one	230-236	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	70-78